Health and Rehabilitation Research Institute, AUT University, Akoranga Drive, Northcote, Auckland 1142, New Zealand.
BMC Musculoskelet Disord. 2013 May 1;14:156. doi: 10.1186/1471-2474-14-156.
Despite numerous methodological flaws in previous study designs and the lack of validation in primary care populations, clinical tests for identifying acromioclavicular joint (ACJ) pain are widely utilised without concern for such issues. The aim of this study was to estimate the diagnostic accuracy of traditional ACJ tests and to compare their accuracy with other clinical examination features for identifying a predominant ACJ pain source in a primary care cohort.
Consecutive patients with shoulder pain were recruited prospectively from primary health care clinics. Following a standardised clinical examination and diagnostic injection into the subacromial bursa, all participants received a fluoroscopically guided diagnostic block of 1% lidocaine hydrochloride (XylocaineTM) into the ACJ. Diagnostic accuracy statistics including sensitivity, specificity, predictive values, positive and negative likelihood ratios (LR+ and LR-) were calculated for traditional ACJ tests (Active Compression/O'Brien's test, cross-body adduction, localised ACJ tenderness and Hawkins-Kennedy test), and for individual and combinations of clinical examination variables that were associated with a positive anaesthetic response (PAR) (P≤0.05) defined as 80% or more reduction in post-injection pain intensity during provocative clinical tests.
Twenty two of 153 participants (14%) reported an 80% PAR. None of the traditional ACJ tests were associated with an 80% PAR (P<0.05) and combinations of traditional tests were not able to discriminate between a PAR and a negative anaesthetic response (AUC 0.507; 95% CI: 0.366, 0.647; P>0.05). Five clinical examination variables (repetitive mechanism of pain onset, no referred pain below the elbow, thickened or swollen ACJ, no symptom provocation during passive glenohumeral abduction and external rotation) were associated with an 80% PAR (P<0.05) and demonstrated an ability to accurately discriminate between an PAR and NAR (AUC 0.791; 95% CI 0.702, 0.880; P<0.001). Less than two positive clinical features resulted in 96% sensitivity (95% CI 0.78, 0.99) and a LR- 0.09 (95% CI 0.02, 0.41) and four positive clinical features resulted in 95% specificity (95% CI 0.90, 0.98) and a LR+ of 4.98 (95% CI 1.69, 13.84).
In this cohort of primary care patients with predominantly subacute or chronic ACJ pain of non-traumatic onset, traditional ACJ tests were of limited diagnostic value. Combinations of other history and physical examination findings were able to more accurately identify injection-confirmed ACJ pain in this cohort.
尽管先前的研究设计存在众多方法学缺陷,且在初级保健人群中缺乏验证,但临床用于识别肩锁关节(ACJ)疼痛的检查仍被广泛应用,而不考虑这些问题。本研究旨在评估传统 ACJ 检查的诊断准确性,并比较其在初级保健队列中识别主要 ACJ 疼痛来源的准确性与其他临床检查特征。
连续前瞻性招募来自初级保健诊所的肩部疼痛患者。在进行标准化临床检查和肩胛下囊诊断性注射后,所有参与者均接受了氟透视引导的 1%盐酸利多卡因(XylocaineTM)关节内阻滞。为传统 ACJ 检查(主动压缩/奥布赖恩试验、交叉体侧方内收、局部 ACJ 压痛和霍金斯-肯尼迪试验)和与阳性麻醉反应(PAR)相关的个体和临床检查变量组合(定义为在激发性临床检查期间疼痛强度降低 80%或以上)计算诊断准确性统计数据,包括敏感性、特异性、预测值、阳性和阴性似然比(LR+和 LR-)。
在 153 名参与者中,有 22 名(14%)报告了 80%的 PAR。没有一种传统的 ACJ 检查与 80%的 PAR 相关(P<0.05),且传统检查的组合也无法区分 PAR 和阴性麻醉反应(AUC 0.507;95%CI:0.366,0.647;P>0.05)。五个临床检查变量(疼痛发作的重复机制、肘部以下无牵涉痛、ACJ 增厚或肿胀、被动盂肱外展和外旋时无症状激发)与 80%的 PAR 相关(P<0.05),并具有准确区分 PAR 和 NAR 的能力(AUC 0.791;95%CI 0.702,0.880;P<0.001)。少于两个阳性临床特征的敏感性为 96%(95%CI 0.78,0.99),LR-为 0.09(95%CI 0.02,0.41),而四个阳性临床特征的特异性为 95%(95%CI 0.90,0.98),LR+为 4.98(95%CI 1.69,13.84)。
在本队列中,主要为非创伤性发病的亚急性或慢性 ACJ 疼痛的初级保健患者中,传统 ACJ 检查的诊断价值有限。其他病史和体格检查结果的组合能够更准确地识别该队列中经注射证实的 ACJ 疼痛。